Clinical Trial

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Status change: Not Yet Recruiting → Recruiting 2026-03-03
Trial Details
NCT Number NCT06951503
Lead Sponsor Akeso
Conditions Colorectal Adenocarcinoma
Enrollment 560 participants
Start Date 2025-05-27
Primary Completion 2027-01-13 (estimated)
Study Completion 2029-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-04